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Abstract: The recent emergence of cancer immunotherapies initiated a significant shift in the clinical
management of metastatic melanoma. Prior to 2011, melanoma patients only had palliative treatment
solutions which offered little to no survival benefit. In 2018, with immunotherapy, melanoma patients
can now contemplate durable or even complete remission. Treatment with novel immune checkpoint
inhibitors, anti-cytotoxic T-lymphocyte protein 4 and anti-programmed cell death protein 1, clearly result
in superior median and long-term survivals compared to standard chemotherapy; however, more than half
of the patients do not respond to immune checkpoint blockade. Currently, clinicians do not have any
effective way to stratify melanoma patients for immunotherapies. Research is now focusing on identifying
biomarkers which could predict a patient’s response prior treatment initiation (or very early during
treatment course), in order to maximize therapeutic efficacy, avoid unnecessary costs, and undesirable
heavy side effects for the patient. Given the rapid developments in this field and the translational potential
for some of the biomarkers, we will summarize the current state of biomarker research for immunotherapy
in melanoma, with an emphasis on omics technologies such as next-generation sequencing and mass
cytometry (CyTOF). Immunotherapy has revolutionized the management of metastatic melanoma. Prior
to 2011, the median survival for metastatic melanoma was 9 months, compared to greater than 18 months
in 2017 (1). Patients now benefit from novel immune checkpoint inhibitors (ICIs), anti-cytotoxic T-
lymphocyte protein 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1). From the latest
survival data of the Checkmate 067 trial, progression-free survival (PFS) for ipilimumab is 2.9 months,
for nivolumab 6.9 months, and for the combination of nivolumab and ipilimumab 11.5 months. Overall
survival (OS) of the ipilimumab group was 19.9 and 37.6 months for the nivolumab group. Median OS
was not reached in the combination nivolumab and ipilimumab group with a minimum follow-up time of
36 months (2–6). Although OS is extended, not all patients benefit from immunotherapy. Response rates
for ipilimumab range from 11% to 19% (4, 5) and for pembrolizumab or nivolumab from 33% to 44%
(2, 6, 7). These new ICIs clearly show superior median and long-term survivals compared to standard
chemotherapy; however, more than half of the patients do not respond to immune checkpoint blockade.
Currently, there are no clinically approved biomarkers to aid in patient selection in melanoma. In this
review, we seek to delineate the current state of biomarker research for immunotherapy in melanoma,
with an emphasis on omics technologies such as next-generation sequencing (NGS) and mass cytometry
(CyTOF). Given the urgent clinical need for such biomarkers, we decided to focus on human studies only,
which we think are more clinically relevant.
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The recent emergence of cancer immunotherapies initiated a significant shift in the clinical 
management of metastatic melanoma. Prior to 2011, melanoma patients only had palli-
ative treatment solutions which offered little to no survival benefit. In 2018, with immuno-
therapy, melanoma patients can now contemplate durable or even complete remission. 
Treatment with novel immune checkpoint inhibitors, anti-cytotoxic T-lymphocyte protein 
4 and anti-programmed cell death protein 1, clearly result in superior median and long-
term survivals compared to standard chemotherapy; however, more than half of the 
patients do not respond to immune checkpoint blockade. Currently, clinicians do not 
have any effective way to stratify melanoma patients for immunotherapies. Research 
is now focusing on identifying biomarkers which could predict a patient’s response 
prior treatment initiation (or very early during treatment course), in order to maximize 
therapeutic efficacy, avoid unnecessary costs, and undesirable heavy side effects for 
the patient. Given the rapid developments in this field and the translational potential 
for some of the biomarkers, we will summarize the current state of biomarker research 
for immunotherapy in melanoma, with an emphasis on omics technologies such as 
next-generation sequencing and mass cytometry (CyTOF).
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Immunotherapy has revolutionized the management of metastatic melanoma. Prior to 2011, the 
median survival for metastatic melanoma was 9 months, compared to greater than 18 months in 
2017 (1). Patients now benefit from novel immune checkpoint inhibitors (ICIs), anti-cytotoxic 
T-lymphocyte protein 4 (CTLA-4) and anti-programmed cell death protein 1 (PD-1). From the 
latest survival data of the Checkmate 067 trial, progression-free survival (PFS) for ipilimumab is 
2.9  months, for nivolumab 6.9  months, and for the combination of nivolumab and ipilimumab 
11.5  months. Overall survival (OS) of the ipilimumab group was 19.9 and 37.6  months for the 
nivolumab group. Median OS was not reached in the combination nivolumab and ipilimumab group 
with a minimum follow-up time of 36  months (2–6). Although OS is extended, not all patients 
benefit from immunotherapy. Response rates for ipilimumab range from 11% to 19% (4, 5) and 
for pembrolizumab or nivolumab from 33% to 44% (2, 6, 7). These new ICIs clearly show superior 
median and long-term survivals compared to standard chemotherapy; however, more than half 
of the patients do not respond to immune checkpoint blockade. Currently, there are no clinically 
approved biomarkers to aid in patient selection in melanoma. In this review, we seek to delineate the 
current state of biomarker research for immunotherapy in melanoma, with an emphasis on omics 
technologies such as next-generation sequencing (NGS) and mass cytometry (CyTOF). Given the 
urgent clinical need for such biomarkers, we decided to focus on human studies only, which we think 
are more clinically relevant.
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iMMUNe CHeCKPOiNTS
CTLA-4 and PD-1 are two immune checkpoints regulating 
immune homeostasis. CTLA-4 is a negative regulator of T-cell 
priming that acts to control naïve T-cell activation by competing 
with the co-stimulatory molecule CD28 for binding to shared 
ligands CD80 and CD86 on antigen-presenting cells (APCs) in 
the lymph node (8). Ipilimumab, a monoclonal antibody against 
CTLA-4, was the first agent approved for the treatment of unre-
sectable or metastatic melanoma that showed an OS benefit in a 
randomized phase III trial (4). PD-1 is a T-cell exhaustion marker 
which is upregulated by T-cells upon activation during priming 
or expansion and binds to one of two ligands: programmed cell 
death 1-ligand 1 (PD-L1) and -ligand 2 (PD-L2) (9–11). Pem-
brolizumab and nivolumab are monoclonal antibodies against 
PD-1 that have both shown OS benefit in randomized phase III 
trials and are approved for the treatment of metastatic mela-
noma (2, 7). Furthermore, nivolumab and pembrolizumab have 
both improved OS compared with ipilimumab in metastatic 
melanoma patients that are naïve to both agents. Combination 
therapy with ipilimumab and nivolumab has demonstrated 
additional clinical activity with objective response rates ranging 
from 50% to 60% and improved OS compared to ipilimumab 
alone. Although ipilimumab, nivolumab, and pembrolizumab 
have significantly improved the survival of melanoma patients, 
there are major toxicities associated with the use of these drugs 
[reviewed in Ref. (12)]. Grade 3 and higher adverse events are 
seen in about 20% of patients treated with ipilimumab, in 15% of 
patients treated with nivolumab, and in 50% of patients treated 
with the combination of both drugs (6). As these therapies 
result in objective responses for only a subset of patients, there 
is a crucial need to identify biomarkers that can potentially 
predict the efficacy of anti-CTLA-4 or anti-PD-1 treatment 
or identify a specific subset of patients who may benefit from 
immunotherapy. A summary of current potential biomarkers 
for immunotherapies in metastatic melanoma patients is listed 
in Figure 1.
CLiNiCAL BiOMARKeRS
Approved markers for melanoma monitoring have not sub-
stantially evolved over the past decade. Clinicians have mainly 
used the TNM staging system as a diagnostic and prognostic 
indicator. In 2009, lactate dehydrogenase (LDH) was shown 
to be an independent predictor of survival in melanoma and 
was therefore added to the AJCC guidelines (13). Accelerated 
metabolism in cancer cells requires increased glycolysis that cre-
ates a high amount of LDH as a byproduct, which is therefore a 
robust proxy to assess tumor burden (14). It is the only accepted 
serum biomarker with prognostic value for OS in melanoma (15). 
In the context of immunotherapies, elevated LDH is a negative 
prognostic marker for patients treated with ipilimumab (16) and 
with pembrolizumab (17, 18). However, subgroup analysis of 
anti-PD-1 treated cohorts recently pointed out that LDH level is 
not correlated with the duration of response (KEYNOTE-006). 
Indeed, once patients show response to the treatment, the LDH 
level is not associated with the duration of the remission period. 
As described by Diem et al. in a study specifically assessing the 
role of LDH as a marker for anti-PD-1 therapy, LDH is never-
theless a useful marker to monitor disease progression and help 
treatment decisions (19).
Another well-known marker to monitor melanoma is S100, 
which is a good indicator of advanced clinical disease stage (20). 
S100 was shown to be predictive of response to anti-CTLA-4 
(16). However, similar to LDH, S100 seems to mainly be a proxy 
of disease stage, able to highlight very ill patients who are more 
unlikely to respond to the treatment due to the high tumor 
burden of the disease, but not actually able to predict response 
to immunotherapies. The same is true for the number of organs 
involved, which was another potential marker, proposed by Diem 
et al., to stratify patients prior to anti-CTLA-4 therapy (21).
C-reactive protein (CRP) was described as a negative prog-
nostic factor for anti-CTLA-4 treatment (22). Unlike LDH and 
S100, CRP is directly related to immune response. However, it is a 
general marker of inflammation and is not specific to melanoma, 
ergo, an increase in CRP levels may also be the result of any other 
ongoing infection (23). For anti-PD-1 therapy, intra-tumoral 
PD-L1 expression, evaluated by immunohistochemistry, has been 
assessed as a predictive biomarker. The results have been incon-
clusive due to a lack of standards for PD-L1 “positivity”. Different 
antibodies and different evaluation criteria have been used for 
PD-L1 expression in clinical trials. Some studies have used a >5% 
cutoff (Checkmate-066 and Checkmate-067), whereas others have 
used >1% cutoff (KEYNOTE-006). In the Checkmate-066 trial, 
both PD-L1 negative and positive patients had better outcomes 
than chemotherapy-treated patients, suggesting that PD-L1 
status was not a relevant stratification marker (2). More research 
will be needed to standardize the assessment of PD-L1 expression 
for it to become a biomarker for anti-PD-1 therapy in melanoma. 
Blood markers which hold the most potential toward predicting 
response to immunotherapies are immune cell populations. 
Indeed, they are either themselves part of or directly influencing 
the immune response against the tumor. The different findings 
related to blood cytology as a biomarker for immunotherapy in 
melanoma are summarized in Figure 1. Briefly, for anti-CTLA-4 
treatment, absolute neutrophil count, absolute lymphocyte count, 
neutrophil to lymphocyte ratio, absolute eosinophil count, relative 
lymphocyte count (RLC), absolute monocyte count, antibodies 
against NY-ESO1, T-regulatory cell count, and myeloid-derived 
suppressor cell (MDSC) count have been described as predic-
tive biomarkers. In anti-PD-1-treated patients, RLC, relative 
eosinophil count (REC), and MDSC count seem to hold some 
predictive potential prior to treatment initiation. In addition, 
increased serum levels of TGFβ and increased frequency of 
Th9 cells in the peripheral blood were detected in responders to 
nivolumab prior to therapy initiation (24). Unfortunately, most 
of the studies were performed on small cohorts and the results 
have not been verified in larger prospective trials (25). Although 
guidelines have been published about how to best perform bio-
marker studies (26), most research groups have different evalu-
ation criteria. In this review, we sought to document the most 
relevant biomarkers associated with immunotherapy outcome in 
melanoma patients. For a systematic review of clinical biomarkers, 
see Ref. (18).
FiGURe 1 | Summary of the biomarker studies performed on peripheral blood and tumor on anti-CTLA4 and anti-PD1 treatment.
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BiOMARKeRS FROM NeXT-GeNeRATiON 
SeQUeNCiNG
Whole exome (WES) and RNA sequencing (RNAseq) are power-
ful tools for evaluating the genomic landscape of a tumor. WES 
only captures the exonic gene regions, so it enriches for muta-
tions in coding regions, while RNAseq can provide the entire 
transcriptome of a sample and is useful for establishing gene 
signatures for specific cohorts within a patient group. In terms of 
immunotherapy, WES has been useful in determining mutational 
load and discovering neoantigens in melanoma tumors (27). 
Melanoma has one of the highest mutation rates of all cancers 
(28–30) and has a high probability for neoantigen generation. 
Neoantigens are the result of somatic mutations which translate 
into a mutated protein that is detected and presented by APCs. 
Neoantigens are an attractive target for immunotherapy as they 
are only expressed by the tumor and not by the normal tissue. 
Many studies have utilized WES and RNAseq to evaluate the 
mutation profile and gene expression changes in patients treated 
with anti-CTLA-4 and anti-PD-1, with the aim to find biomark-
ers to predict response.
Snyder et al. performed WES on 64 patients treated with anti-
CTLA-4 (31). This study was the first to associate mutational bur-
den to clinical benefit and they also defined a neoantigen signature 
associated with clinical benefit. They concluded that, although 
patients with high mutation burden are more likely to respond to 
anti-CTLA-4, the types of neoantigen the patient expresses will 
ultimately determine their response. Van Allen et al. performed 
WES on 110 patients and RNAseq on 40 patients treated with 
anti-CTLA-4 (32). They could confirm that mutational load 
is associated with clinical benefit to anti-CTLA-4 treatment. 
Neoantigen load was also measured and this parameter was also 
significantly associated with response; however, they could not 
detect the neoantigen signature seen in the study performed by 
Snyder and colleagues. They concluded that clinically beneficial 
neoantigens are most likely private events (specific to each 
individual) and recurrent neoantigens (consistent in the general 
population) are quite rare. Van Allen and colleagues also analyzed 
the transcriptome in a subset of these patients and found that 
expression of cytolytic markers, such as granzyme A and perforin, 
were beneficial for response. Expression of CTLA-4 and PD-L2 
was also associated with clinical benefit. Riaz et  al. performed 
WES on 174 patients treated with anti-CTLA-4 therapy (33). 
They discovered 48 patients with mutations in SERPINB3 or 
SERPIN4 and observed that those patients were more likely to 
be responders. Patients with SERPINB3 or SERPINB4 mutations 
also had higher mutational loads. Friedlander et al. performed a 
quantitative polymerase chain reaction (PCR) study on periph-
eral blood from 360 patients receiving anti-CTLA-4 therapy (34). 
From a panel of 169 genes, they established a 15 gene signature 
that was predictive and prognostic for response and 1-year OS 
to anti-CTLA-4 treatment. The 15 genes are ITGA4, LARGE, 
CDK2, TIMP1, DPP4, NRAS, ERBB2, NAB2, ADAM17, RHOC, 
TGFB1, CDKN2A, HLADRA, MYC, and ICOS.
In order to elucidate resistance mechanisms and biomarkers 
of response to treatment, Hugo et  al. used WES (38 patients) 
and RNAseq (28 patients) on a set of melanoma patients treated 
with anti-PD-1 (35). Mutational load did not have a significant 
association to response to anti-PD-1 therapy and neoantigen load 
was not significantly correlated with response either. Nonetheless, 
mutational load was associated with OS suggesting that other fac-
tors influence response to anti-PD-1 and survival. BRCA2 muta-
tions occurred in 30% of the responders to anti-PD-1. RNAseq 
analysis uncovered a co-enrichment of 26 gene signatures in 9 of 
the 13 non-responding patients, which the authors termed innate 
anti-PD-1 resistance (IPRES) signature. They validated the IPRES 
signature on three other datasets and found over-representation 
in anti-PD-1 non-responding samples.
In a small study of four patients treated with anti-PD-1, Zaretsky 
et al. used WES on patients that developed new lesions under anti-
PD-1 therapy. They discovered that the progressive tumors acquired 
JAK1, JAK2, or B2M loss of function mutations. JAK1 and JAK2 
mutations cause insensitivity to interferon gamma-induced arrest 
and B2M mutations led to a loss of MHC class 1 expression (36). In 
a follow-up study, Shin et al. performed WES on 23 patients before 
anti-PD-1 treatment (37). In their cohort, mutational load had no 
association to response and one of the non-responders had a loss of 
function mutation in JAK1. This study confirms the role of JAK1 as 
a marker for innate and adaptive resistance to anti-PD-1, although 
it might be a rare occurrence.
Roh et al. performed WES on sequential biopsies of patients 
treated with anti-CTLA-4 and then anti-PD-1. Thirty patients 
had WES at baseline, 3 on anti-CTLA-4 treatment, 25 at anti-
CTLA-4 progression, 18 on anti-PD-1 treatment, and 12 at 
anti-PD-1 progression. Overall, they found that mutation burden 
was not associated with response, but high copy number loss was 
associated with poor response (38). In the regions with recurrent 
copy number loss, PTEN was one of the notable tumor suppressor 
genes suggesting that it could be a driver of resistance mechanisms 
to immunotherapy. Another study also observed that PTEN loss 
was associated with resistance to anti-CTLA-4 therapy (39).
Johnson et  al. performed targeted panel sequencing on 
65 patients treated with anti-PD-1 therapy. In their cohort, 
mutational load was associated with response to anti-PD-1 and 
patients with high mutational load (>23.1 mutations/MB) had 
longer PFS and OS compared to the intermediate mutational 
load group (3.3–23.1 mutations/MB) and the low mutation 
load (<3.3 mutations/MB) group. They observed more frequent 
BRCA2 mutations in responders than in non-responders (5/32 
vs. 2/33). LRP1B mutations were significantly enriched in the 
responder group (11/32) compared to the non-responder group 
(1/33). LRP1B mutated patients also had a higher mutational load 
compared to LRP1B wild-type patients.
Riaz et al. performed WES on 68 patients treated with anti-
PD-1 that had previously progressed on anti-CTLA-4 therapy (35 
patients) or were naïve to anti-CTLA-4 (33 patients). Mutational 
load was associated with clinical benefit in the anti-CTLA-4-
naïve group, but not the anti-CTLA-4-resistant group. No single 
gene mutations were significantly associated with response or 
resistance to therapy. Decreased mutational and neoantigen load 
during therapy was associated with response in both anti-CTLA-
4-naïve and anti-CTLA-4-resistant groups. RNAseq analysis of 
the pretreatment samples showed an enrichment in T-cell acti-
vation and lymphocyte aggregation pathways. These signatures 
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indicate an immunologically active tumor, or “hot tumor,” and 
all patients with complete response or partial response in the 
anti-CTLA-4-resistant group had the “hot tumor” signature, 
although not all responders in the anti-CTLA-4-naïve group had 
the “hot tumor” signature. Riaz et al. also investigated the early 
effects of anti-PD-1 treatment (29 days after start) by RNAseq and 
uncovered a global increase in immune checkpoint genes such as 
PD-1, CTLA-4, CD274 (PD-L1), ICOS, and LAG3 in all samples. 
For responders, the significant pathways included inflammatory 
response and cytokine-mediate signaling pathways.
Finally, Davoli et  al. investigated the role of aneuploidy in 
response to immunotherapy (40). They analyzed the copy number 
data from 5,255 tumor/normal samples, representing 12 cancer 
types from The Cancer Genome Atlas project, and found that for 
most tumors, there was a positive correlation between aneuploidy 
severity and mutational load. They also found that tumors with 
high levels of aneuploidy showed elevated expression of cell cycle 
and cell proliferation markers, as well as a reduced expression of 
markers for cytotoxic immune cell infiltrates. Aneuploidy levels 
were a stronger predictor of markers of cytotoxic immune cell 
infiltration than tumor mutational load. To correlate aneuploidy 
with response to immunotherapy, they used data from Snyder 
et al. and Van Allen et al. (31, 32) and found in both datasets that 
high levels of aneuploidy correlated with poorer survival.
BiOMARKeRS FROM T-CeLL ReCePTOR 
(TCR) PROFiLiNG
Antigen detection by T-cells is by definition dependent on tumor-
specific T-cell generation and clonal amplification. In the context 
of immunotherapies, which aim at enhancing the recognition of 
the cancer cell by the immune system, there is an obvious rational 
basis for examining the T-cell repertoire in order to shed light 
on the specific mode of action of the drug and find potential 
biomarkers of response.
The main challenge when analyzing TCR repertoire is its 
immense diversity. The TCR is a heterodimer comprised of two 
chains αβ or δγ. The β and δ chains, are generated by the random 
rearrangement of a variable region (V), a diversity region (D), and 
a joining region (J) with a constant region (C). The α and γ chains, 
consists of segments from the V, J, and C regions. Additional com-
plexity is introduced by random addition or deletion of nucleo-
tides at the junction sites of V, D, and J. The theoretical limit of the 
TCR repertoire is in the range of 1015, which is several magnitudes 
higher than the total amount of T-cells in the body, approximately 
4 ×  1011 (41). The estimated number for the TCR repertoire is 
in the order of 106 to 108 (42). Most of the studies mainly assess 
the complementarity-determining region 3 (CDR3) from β 
chain, which is considered an acceptable proxy for estimating 
diversity since it is the most variable region of the receptor and 
that αβT-cells represent about 90% of all T-cells (43). Due to the 
advances in NGS, it is possible now to identify each individual 
TCR sequence in the CDR3 region (44). Multiplex PCR is one of 
the widely used methods to amplify the CDR3 region. Primers 
for the J alleles or the constant region of the TCR α and β chains 
are used together with a mix of primers for all known V alleles. 
A drawback of multiplex PCR is that it is limited to known V alleles. 
As a result, for TCR discovery experiments, other methods such as 
targeted enrichment—a technique where RNA baits capture the 
TCR receptor, usually the CDR3 region—are preferred. Since bait 
capture takes into account mismatches, it allows for discovery of 
new alleles and TCR receptors. In the context of immunotherapy, 
TCR repertoire analysis is useful for determining if the tumor-
reactive clones have undergone activation and clonal expansion. 
In an adequate immune response, the tumor-specific T-cells will 
represent a significant proportion of the whole repertoire and 
therefore be assessable at the level of the whole TCR population.
In 2014, Robert et al. compared pre- to post-treatment periph-
eral blood mononuclear cell (PBMC) samples from melanoma 
patients treated with anti-CTLA-4 (45). The results from deep 
sequencing of the multiplex PCR for the TCR Vβ CDR3 region 
showed that 19 out of 21 patients had an increased number of 
unique clonotype (richness). There was no significant difference 
in the V or J segment usage and no difference in the total of 
unique sequences between responders and non-responders. The 
number of unique productive sequences in the top 25% of clones 
showed a particularly high increase in diversity after treatment. 
Those changes were not associated with peripheral lymphocyte 
count; however, CD8+ tumor-infiltrating cells showed a posi-
tive correlation with the TCR repertoire diversity. Finally, they 
showed that patients experiencing more toxicities had more 
diverse sequences post treatment. Overall, this study reports that 
anti-CTLA-4 treatment increases TCR repertoire diversity in an 
unspecific manner. Subsequently, the same group performed a 
similar study on 9 anti-PD-1-treated patients and compared the 
results (46). Unlike the effect of anti-CTLA-4, anti-PD-1 therapy 
does not increase TCR repertoire complexity, on the contrary, 4/9 
samples show a decrease >15% in the absolute number of unique 
sequences and only one had an increase >15%. Those results 
suggest that the mode of action of the two drugs is considerably 
different.
Cha et  al. shed more light on the potential mechanism of 
anti-CTLA-4; their study assessed the changes in TCR repertoire 
between baseline and 4 weeks of treatment in PBMCs from 21 
melanoma patients (47). They confirmed that anti-CTLA-4 treat-
ment induces a significant change in the clonotypes frequency 
compared to healthy donors. They showed that the diversification 
is the result of a higher gain of new clonotypes and lower loss of 
existing ones. The number of therapy-induced expanding clones 
are not different between the responders and the non-responders, 
which is in line with what Robert et  al. described. However, 
patients who survived longer exhibited less clonotypic changes 
overtime, they maintained the most abundant clones which 
were present at baseline and also had fewer clones significantly 
decreasing in frequency. Finally, they also demonstrated that the 
clones expanding in response to therapy are largely non-naïve 
T-cells, suggesting that patients who respond to the therapy 
already have pre-primed T-cells in circulation before the onset of 
anti-CTLA-4 treatment.
In light of these findings, Postow et al. hypothesized that the 
shape of the TCR repertoire prior to treatment initiation may 
influence the likelihood of a response to the treatment (48). Twelve 
baseline PBMC samples from 4 responders and 8 non-responders 
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to anti-CTLA-4 were analyzed for richness and evenness of the 
TCR repertoire. In this small cohort, they first showed that 
patients who responded to the treatment have more similar VJ 
usage among each other than compared to the VJ usages in the 
non-responders. Furthermore, low richness or evenness of the 
TCR repertoire was significantly associated with a poor response 
to anti-CTLA-4. That is, a TCR repertoire composed of less unique 
clones (less diverse) or skewed toward a few specific clones (very 
clonal) is predictive of a non-response to the treatment.
The detection of clonally expanded tumor-specific T-cell in 
the blood indicates that the immune system mounted an immune 
response against a foreign entity, which could be the tumor. 
However, it is not certain that the activated T-cells would be able 
to home to the tumor efficiently and be able to kill the cancer 
cells. Therefore, it is also important to assess the immune status 
at the tumor site.
Tumeh et al. performed a very elegant study exploiting tumor 
samples from melanoma patients prior and during anti-PD-1 
treatment (49). By qualitative and quantitative immunohisto-
chemistry, they revealed that, at baseline, patients who eventually 
respond to the therapy, have more CD8+ T-cells at the invasive 
margin of the tumor compared to non-responders. This popula-
tion increases and migrates toward the center of the tumor during 
treatment in responders. They showed that an efficient response 
to anti-PD-1 therapy requires pre-existing CD8+ T-cells, which 
are most likely tumor specific. To confirm this theory, they 
sequenced the TCR Vβ region of tumor baseline samples and 
found that responders indeed had a more clonal TCR repertoire. 
On treatment, samples of responders showed significantly more 
clonal expansion than non-responders.
Johnson et al. used NGS to assess differences between baseline 
samples of responders and non-responders to anti-PD-1 therapy 
(50). They assessed mutational load as well as specific mutations 
differentially occurring in responders and non-responders. They 
also investigated the TCR repertoire clonality of 42 samples 
and did not find any association with response. However, it is 
important to mention that times of sample acquisition were not 
immediately before and after treatment. The timing was quite 
broad, the study allowed the inclusion of samples collected over 
12 months before start of treatment and also after treatment initia-
tion. When the analysis was performed only on samples obtained 
within 4 months of treatment initiation, the non-responder group 
was only represented by five samples, including one potential 
outlier. Nonetheless, they noticed a trend toward higher clonality 
at baseline in patients who eventually responded to the therapy.
Inoue et al. analyzed the TCR repertoire of 10 pre- and post- 
anti-PD-1 tumor samples (51). They noticed that the clonotypes 
with a read frequency >0.5% at baseline significantly increased 
after treatment in responders. The calculation of the diversity 
index highlighted a slight decrease in tumors of responders com-
pared to non-responders, which suggests oligoclonal expansion 
of certain TCR clones.
More recently, Roh et al. published a complementary analysis 
on a cohort of patients for which they performed TCR sequenc-
ing (38). They analyzed tumor samples from melanoma patients 
treated sequentially with anti-CTLA-4 and anti-PD-1 via WES and 
TCR sequencing. The TCR clonality assay revealed that there was 
no significant difference between responders and non-responders, 
pre- or on-treatment with anti-CTLA-4. A subpopulation of the 
patients (n = 8) received anti-CTLA-4 followed by anti-PD-1 after 
progression. All three responders to anti-CTLA-4 followed by anti-
PD-1 showed an increase in TCR clonality during anti-CTLA-4 
treatment. In addition, higher TCR clonality was seen in the 
responders prior to treatment and on treatment with anti-PD-1.
Riaz et al. investigated the evolution of melanoma tumors and 
their microenvironment under anti-PD-1 therapy (52). Patients 
who had previously progressed on anti-CTLA-4 and were naïve 
to anti-CTLA-4 were included in the study. They performed TCR 
sequencing on 34 samples pre- and 4  weeks post- anti-PD-1 
treatment. There were no statistically significant differences 
in the baseline samples of either group. On anti-PD-1 therapy, 
the anti-CTLA-4-pretreated group had increased TCR richness 
associated with response, whereas the anti-CTLA-4-naïve group 
had decreased TCR evenness associated with response. In line 
with Roh et al., pretreatment with anti-CTLA-4 seems to increase 
the expansion of tumor-specific T-cell cells, which are addition-
ally expanded during anti-PD-1 treatment.
MASS CYTOMeTRY (CyTOF)
The advent of CyTOF has allowed a more comprehensible analy-
sis of the whole immune system and will be an important asset for 
immune oncology (53). The basic principle of CyTOF is similar 
to conventional flow cytometry. The assay quantifies multiple 
protein expression markers at the single-cell level. In contrast 
to flow cytometry, the detection is not achieved by fluorophore 
excitation, but by stable mass isotope quantification. The transi-
tion isotope bound to the antibodies are analyzed by a time of 
flight mass spectrometer. CyTOF has some advantages over flow 
cytometry, namely, the high purity of the metal isotopes reduces 
background noise, eliminating spectral spillover and cellular 
autofluorescence associated with conventional flow cytometry. It 
also enables the detection of more markers in the same experi-
ment, theoretically up to a hundred. Multiple samples can be 
analyzed at the same time thanks to a barcoding strategy (up 
to 20), and therefore reduce inter-sample variation. CyTOF has 
primarily been used to analyze peripheral blood from patients 
undergoing immunotherapy. A better characterization of the 
precise mode of action of those drugs is crucial to help overcom-
ing and predicting resistance as well as contributing to optimal 
development of future combination therapies.
In 2015, Das et  al. analyzed peripheral blood from mela-
noma patients undergoing immunotherapy with anti-CTLA-4, 
anti-PD-1, or the combination of the two (54). Samples were 
collected at baseline and after 3 weeks of treatment. In this early 
study, CyTOF was mainly used to further characterize the cell 
population of interest previously identified by flow cytometry. The 
analysis revealed that the Ki67+ cells, increasing after combina-
tion treatment, have a transitional memory T-cell-like phenotype. 
Additional experiments were performed using other techniques 
than CyTOF, which lead the authors to conclude that anti-PD-1 
and anti-CTLA-4 have distinct effects on the immune system.
In the context of a clinical trial assessing the safety of combin-
ing radiotherapy and immunotherapy in melanoma patients, 
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Hiniker et  al. analyzed baseline and follow-up PBMC samples 
from 9 patients (3 progressive disease, 6 complete response/
partial response) (55). CyTOF analysis revealed that the level 
of CD8+ T-cells expressing IL-2 were higher at baseline and in 
the follow-up samples of responding patients. The same was true 
for central memory CD8+ T-cell levels. However, the cytokine 
production was not significantly different from the population 
seen in non-responding patients, thereby suggesting that the cells 
are not functionally different from the non-responders.
The first study to use CyTOF as a main technique for analyzing 
human melanoma patient samples was performed by Wistuba-
Hamprecht et  al. in early 2017 (56). The analysis consisted 
in performing CyTOF on 28 PBMC samples from stage IV 
melanoma patients who received different courses of treatments. 
A higher frequency in the APC-like population had a positive 
association with OS, whereas a higher frequency in the MDSC-
like population showed negative association with OS. Overall, an 
equal abundance of MDSC- and APC-like cells is associated with 
better survival. The analysis of the T-cell compartment revealed 
that there was a clear interpatient heterogeneity in the CD4+ and 
CD8+ T-cell compartments compared to the other compartments 
which have more homogenous frequencies between patients. 
Only one αβT-cell population had some prognostic potential: 
a higher level of early differentiated CD4+ T-cell was correlated 
with poorer OS. In the natural killer cell compartment, a highly 
cytotoxic cell population tends to correlate with better OS. 
Finally, a comprehensive analysis of immune signatures of all 
the melanoma-associated phenotypes identified a specific cluster 
with high prognostic capacity, performing even better than LDH. 
This cluster is significantly associated with poor OS and repre-
sented by an overall lower diversity across all the compartments, 
and especially in the myeloid compartment.
Takeuchi et  al. investigated the effect of immunotherapy 
in melanoma patients by comparing PBMCs from 4 different 
patients receiving anti-PD-1 (2 responders and 2 non-responders) 
(57). The panel was composed of 35 markers and they used high-
dimensional clustering to analyze the data. The main finding in 
this paper is that CD4+ and CD4+CD8+ cell populations increase 
during therapy. CD4+CD27+FAS− central memory T-cell were 
shown to expand in a higher proportion in responders than in 
non-responders. These results were validated in a separate cohort 
(n = 4).
More recently, Krieg et  al. performed a comprehensive 
analysis, assessing the correlation between baseline peripheral 
immune signature and response to anti-PD-1 in melanoma 
patients (58). The cohort was composed of 20 patients from whom 
baseline and on treatment samples were obtained. They used an 
optimized immune marker panel and a customized, interactive 
bioinformatics pipeline in order to identify potential predictive 
biomarkers. Three different CyTOF panels were used: one for the 
phenotypic characterization of lymphocytes, one to assess the 
T-cell functions, and the third one to characterize monocytes, 
which consisted of 30, 26, and 25 markers, respectively. By per-
forming hierarchical clustering of all the samples pooled together, 
they identified a differential marker expression in responders 
compared to non-responders. Further analysis, and validation in 
an independent, blinded cohort by conventional flow cytometry, 
revealed that, at baseline, responders had a higher frequency of 
classical monocytes and lower frequency of lymphocytes com-
pared to the non-responders.
OUTLOOK
The development of high-throughput technologies such as NGS 
and CyTOF have allowed researchers and clinicians to evaluate 
hundreds to tens of thousands of genes from a bulk tumor to a 
single-cell level. NGS is an invaluable tool for analyzing mutations 
and copy number profiles, gene expression changes and gene sig-
natures, epigenetic alterations, the TCR repertoire, and single-cell 
gene expression changes. The recent development of CyTOF has 
also allowed the analysis of many markers at a single-cell level. In 
the context of immunotherapy, these high dimensional datasets 
will enhance the discovery of novel biomarkers, prognostic mark-
ers, and resistance mechanisms.
Next-generation sequencing biomarker discovery for anti-
CTLA-4 treatment have uncovered that mutational load and 
neoantigen load are the most informative for response and OS, 
but they are not perfect biomarkers as some non-responders may 
also present with high mutational load. Aneuploidy could also 
help foresee response to anti-CTLA4 since it was highlighted as an 
independent predictor in a multivariate Cox model which included 
mutational load. Copy number analysis could as well be informa-
tive as loss in chromosome 10 was shown to be a poor prognostic 
marker in two studies. Many of these studies also analyzed tumor 
samples upon progression and found no recurrent genetic muta-
tion, which could mean that resistance to anti-CTLA-4 is patient 
specific. In the context of anti-PD-1 treatment, mutational load 
is not a clear informative marker for response. As anti-PD-1 is 
a relatively new therapy, no large cohort studies with over 100 
patients for NGS biomarker discovery have yet been performed. 
There are single patient examples showing that genes involved 
in the JAK–STAT pathway or antigen presentation could be 
predictive biomarkers for anti-PD-1 treatment. Loss of function 
mutations in JAK1, JAK2, and B2M are negative biomarkers for 
response and are involved in resistance to anti-PD-1 treatment in 
individual cases, but these mutations do not seem to be recurrent. 
RNAseq analysis from several studies suggest that tumors with 
high immune activity are more likely to respond to anti-PD-1. To 
better stratify patients for anti-CTLA-4 or anti-PD-1 treatment, a 
combinatorial approach investigating WES, copy number varia-
tion, and RNAseq would be needed.
Overall, most studies support that anti-CTLA-4 and anti-
PD-1 modulate TCR repertoire clonality upon treatment. This 
strengthens the notion that tumor-specific T-cell populations 
are affected by CTLA-4 or PD-1 inhibition. In summary, most 
studies support that anti-CTLA-4 induces an expansion of 
clones in a non-specific manner and, therefore, broadens the 
TCR repertoire. On the other hand, anti-PD-1 seems to favor 
the proliferation of fewer specific clones giving rise to a more 
skewed repertoire, thereby suggesting that the baseline TCR 
repertoire of the patients plays a role in the response to the treat-
ment. However, for the moment, those predictions arise mainly 
from early on-treatment evaluations that examined the evolution 
of the repertoire from baseline, as we are not yet able to precisely 
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pinpoint the tumor-specific clones that, once clonally expanded, 
will facilitate tumor elimination. It is also important to highlight 
that the mode of action of the current immunotherapies are still 
debated and we do not fully comprehend their overall impact 
on different immune cell subpopulations. As a result, it is dif-
ficult to assess the global impact of the drugs on the immune 
response by investigating specific mechanisms individually. This 
is why high-throughput techniques discussed here are powerful 
emerging tools, which will allow us to elucidate this problem 
by looking at numerous markers simultaneously. The more we 
increase our knowledge of exact mechanisms, the better we 
will be able to exploit the therapies by using them in a targeted/
patient-specific manner. Interesting work by Twyman-Saint et al. 
combining anti-CTLA-4, anti-PD-1 and radiotherapy, underpins 
this assertion (59).
To our knowledge, despite the great potential held by CyTOF 
technology, to date, no research was published on the analysis of 
human melanoma tumor samples in the context of immunothera-
pies. One should however expect to see more forthcoming data, 
thanks to a novel exciting add-on technology that is starting to 
emerge. Indeed, a new laser system can be coupled to the CyTOF 
device which allows for imaging mass cytometry (60). That is, 
the detection of metal-labeled antibodies, as in standard CyTOF 
analysis, but performed on tissue sections by using multiplexed 
ion beam imaging. This state of the art technology will allow, not 
only to assess a high range of markers at the same time, but also 
to obtain spatial resolution and warrant a very comprehensive 
analysis of the cell–cell interaction in the tumor microenviron-
ment. New developments of the system should soon facilitate 
the analysis of tumor samples in a similar fashion, while gaining 
spatial resolution to better interrogate the role of spatial interac-
tions in immunotherapy response (with high throughput) (61).
In conclusion, the use of NGS and CyTOF has great potential 
to discover novel biomarkers for immunotherapy and the studies 
discussed above show exciting promises, but need to be further 
validated before clinical application. New prospective trials with 
large cohorts could include these technologies as a biomarker 
discovery platform and could validate many of these findings. In 
parallel, new algorithms to integrate multiple high dimensional 
datasets are being developed for a combinatorial biomarker 
approach, which could use these existing datasets as a training 
model. As NGS is becoming a standard service in many clinics, 
the development of next generation biomarkers should ultimately 
improve the stratification of patients for immunotherapy and 
thereby extend OS for these patients.
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